Enjoy complimentary customisation on priority with our Enterprise License!
The Smoking Cessation and Nicotine De-addiction Market size is estimated to grow by USD 24.52 billion at a CAGR of 12.59% between 2022 and 2027. The surge in online retail adoption facilitates consumers' access to smoking cessation products, propelling market expansion. Moreover, the escalating endeavor to quit smoking, propelled by health anxieties and awareness initiatives, augments the demand for such products. Furthermore, the burgeoning health consciousness among consumers, prompting a transition towards healthier lifestyles, bolsters the need for smoking cessation goods and services. Collectively, these factors engender fresh prospects for smoking cessation market players to innovate and diversify their offerings. However, market growth encounters hurdles like health concerns linked with cessation products, the escalating use of e-cigarettes among adolescents, and stringent regulatory frameworks. Overcoming these challenges necessitates stringent quality assurance measures, targeted educational campaigns, and collaborative efforts to enforce regulations effectively. By navigating through these obstacles, companies can harness the growth opportunities inherent in the smoking cessation market while promoting public health initiatives.
To learn more about this report, Request Free Sample
This market research report extensively covers market segmentation by distribution channel (drug stores and retailers, hospital pharmacies, and online retail), product (e-cigarette, NRT, and drug therapy), and geography (North America, Europe, Asia, and the Rest of the World (ROW)).
The market share growth by the drug stores and retailers segment will be significant during the forecast period. The drug stores and retailers segment is a major market segment in 2022. The Tobacco industry continues to dominate the global market for Smoking Cessation and Nicotine De-addiction, with Nicotine being the primary alkaloid responsible for addiction. Neurotransmitters, such as dopamine and acetylcholine, play a significant role in Nicotine's addictive properties. Various forms of Nicotine replacement therapies (NRT), including lozenges, gum, Nicotine sprays, Nicotine transdermal patches, and sublingual tablets, are commonly used to mitigate Nicotine cravings and alleviate symptoms of withdrawal, such as irritability, anxiety, dysphoria, and hedonic dysregulation. Drug therapy, in the form of Zyban and Chantix, targets the neurochemical processes underlying Nicotine addiction. These medications work by modifying the action of neurotransmitters, reducing the desire to smoke. Nicotine inhalers and e-cigarettes are alternative delivery methods for Nicotine, offering smokers a more familiar experience while reducing their exposure to harmful chemicals.
Get a glance at?the market contribution of various segments Request a PDF Sample
The drug stores and retailers segment showed a gradual increase in market share with 11.21 billion in 2017. Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.
Despite the availability of these treatments, chronic diseases, including lung cancer and asthma, continue to plague smokers. To combat this, vendors are expanding their offerings to include emerging drugs, such as Cytisinicline (cytisine), which is currently undergoing Phase III study, like the ORCA-3 study. Drug Class Insights and other market research firms provide valuable insights into the latest developments in the Smoking Cessation and Nicotine De-addiction market. Non-nicotinic pharmacological therapies and behavioral therapies, including counseling, are also gaining popularity as effective methods for Nicotine/tobacco dependence treatment. Battery-powered devices, such as gums, inhalers, and tablets, are essential tools in the fight against Nicotine addiction. As the market evolves, it is crucial to stay informed about the latest advancements and treatments to ensure the best possible outcomes for those seeking to quit smoking.
For more insights on the market share of various regions Request PDF Sample now!
North America is projected to contribute 32% by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market in North America is expected to register high growth during the forecast period as many people are trying to quit cigarette in this region. The smoking cessation and nicotine de-addiction market in North America is experiencing significant growth, driven by the increasing number of individuals seeking to quit smoking in this region. In 2022, the US accounted for the largest revenue share in the market. The CDC reports that tobacco use results in approximately 7 million deaths annually, with over 480,000 deaths attributable to cigarette smoking and over 41,000 deaths due to passive smoking in the US alone. Nicotine addiction is a major health concern, leading to various diseases such as respiratory disorders, cancer, and heart diseases. Several pharmaceutical companies, including Achieve Life Sciences, Axsome Therapeutics, and NFL Biosciences, are developing innovative solutions to address this issue. For instance, Bupropion and Varenicline are FDA-approved medications used to help individuals quit smoking by reducing cravings and nicotine withdrawal symptoms. Medicaid and Medicare, two prominent healthcare programs in the US, cover the cost of these medications, making them more accessible to a larger population.
Smoking cessation and nicotine de-addiction are significant global health concerns due to the harmful effects of tobacco and its alkaloid, nicotine. Nicotine, a highly addictive neurotransmitter, is found in various tobacco products such as nicotine lozenges, gums, sprays, transdermal patches, sublingual tablets, inhalers, and e-cigarettes. Drug therapy plays a crucial role in smoking cessation, with FDA-approved medications like Zyban (bupropion) and Chantix (varenicline) being widely used. Cytisinicline (cytisine), a non-nicotinic pharmacological therapy, is also undergoing Phase III studies, as per the ORCA-3 study. Behavioral therapies, including counseling, are also effective in smoking cessation. Achieve Life Sciences is developing a novel nicotine degrading enzyme to address the global smoking cessation market. The market for nicotine de-addiction is expected to grow due to the increasing awareness of chronic diseases caused by tobacco use. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The rising adoption of online retailing is notably driving the market growth. The global market for smoking cessation and nicotine de-addiction has witnessed significant growth due to the increasing awareness of the harmful effects of tobacco and nicotine on neurotransmitters in the brain. Tobacco, an alkaloid found in cigarettes, contains harmful chemicals that contribute to chronic diseases such as lung cancer and asthma. Nicotine, the addictive substance in tobacco, acts as a neurotransmitter in the brain, leading to irritability, anxiety, dysphoria, and hedonic dysregulation. Various pharmacological therapies have emerged to aid in nicotine/tobacco dependence treatment. Nicotine replacement therapies (NRTs), including lozenges, gums, sprays, transdermal patches, and sublingual tablets, have been effective in managing nicotine cravings. Drug therapies such as Zyban and Chantix have also shown promise in treating nicotine addiction by targeting the neurotransmitter acetylcholine and blocking the nicotine receptors in the brain. Emerging drugs like cytisine, a plant alkaloid found in the laburnum seed, are currently undergoing Phase III studies, such as the ORCA-3 study, for their potential in smoking cessation. Non-nicotinic pharmacological therapies and behavioral therapies, including counseling, are also effective in treating nicotine addiction. Battery-powered devices like e-cigarettes and inhalers have gained popularity as alternatives to traditional cigarettes.
While they do not contain tobacco, they still deliver nicotine, making it essential to consider their potential health risks. In conclusion, the smoking cessation and nicotine de-addiction market is a growing industry driven by the need to combat the harmful effects of nicotine and tobacco on the body. Pharmacological therapies, including NRTs and drug therapies, as well as non-pharmacological therapies and emerging drugs, offer hope for those seeking to quit nicotine and tobacco use. It is crucial to continue researching and developing new treatments to address the complex nature of nicotine addiction and improve overall public health. Additionally, the proliferation of online pharmacies and drugstores offering nicotine patches and other nicotine replacement therapy (NRT) products is expected to drive market growth in the foreseeable future.
New marketing initiatives are the primary trend driving the market growth. The tobacco industry is witnessing a shift towards marketing initiatives aimed at promoting nicotine de-addiction and smoking cessation. Neurotransmitters, such as dopamine and acetylcholine, play a significant role in nicotine addiction. Various forms of nicotine replacement therapy (NRT) are available, including nicotine lozenges, gums, and sprays, as well as transdermal patches. Drug therapy, such as Zyban and Chantix, which are selective nicotinic acetylcholine receptor agonists and antagonists, respectively, are also effective. Nicotine sublingual tablet and inhaler are other forms of NRT. E-cigarettes, which are battery-powered devices, have gained popularity as an alternative to traditional cigarettes. However, it is essential to note that while e-cigarettes may help some individuals quit smoking, they also contain nicotine and other harmful chemicals, which can contribute to chronic diseases, such as lung cancer and asthma.
Nicotine addiction is a complex condition that can lead to irritability, anxiety, dysphoria, and hedonic dysregulation. COa level, which indicate the amount of carbon monoxide in the blood, can be used to diagnose nicotine addiction. Nicotine replacement therapy and emerging drugs, such as cytisine, which is the active alkaloid in the plant Cytisus laburnum, are undergoing Phase III studies, such as the ORCA-3 study, to assess their efficacy in treating nicotine/tobacco dependence. Non-nicotinic pharmacological therapies and behavioral therapies, including counseling, are also effective in helping individuals quit smoking. It is crucial to understand the various options available and consult with healthcare professionals to determine the most suitable treatment plan. Such marketing campaigns will boost the growth of the market during the forecast period.
Health issues associated with smoking cessation products are the major challenge impeding the market growth. The tobacco industry's shift towards nicotine cessation and de-addiction products, including nicotine lozenges, gum, sprays, and transdermal patches, presents both opportunities and challenges for market growth. Neurotransmitters, such as nicotine, act as powerful alkaloids that stimulate the reward center of the brain, leading to addiction. However, long-term use of these products can result in various health concerns. Nicotine gums, for instance, can cause hair loss, skin irritation, elevated blood pressure, irregular heartbeat, insulin resistance, gastrointestinal issues, and nausea. Moreover, users may experience teeth and jaw problems due to continuous chewing. Nicotine patches, on the other hand, can lead to skin irritation, itching, dizziness, and headaches. Drug therapy, such as Zyban and Chantix, also plays a significant role in smoking cessation. These medications work by modifying the neurochemical processes associated with nicotine addiction, addressing symptoms like irritability, anxiety, dysphoria, and hedonic dysregulation. COa levels, a critical marker of nicotine addiction diagnosis, are significantly reduced with these therapies. Emerging drugs, such as cytisine (Cytisinicline), are undergoing Phase III studies, like the ORCA-3 study, to assess their efficacy in nicotine/tobacco dependence treatment.
Drug Class Insights and other market research firms highlight the potential of non-nicotinic pharmacological therapies and behavioral therapies, including counseling, as viable alternatives to nicotine replacement therapy. Battery-powered devices, such as inhalers and e-cigarettes, have gained popularity as smoking cessation tools. While e-cigarettes have been criticized for their potential health risks due to harmful chemicals, they are still considered a less harmful alternative to traditional cigarettes. The smoking cessation market continues to evolve, with ongoing research and development efforts aimed at addressing the complexities of nicotine addiction and offering effective, safe, and accessible solutions. Thus, awareness about health issues associated with these products is expected to hamper market growth during the market forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates?in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market
Pfizer - The company's key offerings include smoking cessation and nicotine de-addiction guidance. Under its unified segment, the company is engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide.
We also have detailed analyses of the market’s competitive landscape and offer information on 15 market companies, including :
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2023 to 2027, as well as historical data from 2017 to 2021 for the following segments
The market focuses on helping individuals quit smoking and addressing tobacco and nicotine addiction. It offers various solutions like nicotine lozenges, gums, sprays, and transdermal patches to manage withdrawal symptoms. Drug therapy options such as Zyban and Chantix aid in quitting. Nicotine sublingual tablets and inhalers provide alternatives to cigarettes. E-cigarettes are also used, though their safety is debated. The market addresses the health risks of smoking, including lung cancer, COPD (Chronic Obstructive Pulmonary Disease), and asthma, caused by harmful chemicals in cigarettes. Efforts by organizations like the CDC and WHO support smoking cessation through education and policy.
Smoking cessation and nicotine de-addiction are significant health concerns worldwide. Nicotine, a highly addictive substance found in tobacco products, poses numerous health risks. The global market for smoking cessation and nicotine de-addiction is thriving, driven by rising awareness of the health hazards of smoking and the availability of various cessation methods. These include NRTs (Nicotine Replacement Therapies), such as gums, patches, and lozenges, as well as non-pharmacological approaches like counseling and support groups. Additionally, innovative technologies like e-cigarettes and vaping devices are gaining popularity as smoking alternatives. The market is further propelled by demographic shifts, increasing disposable income, and government initiatives to curb tobacco use. Overall, the smoking cessation and nicotine de-addiction market is a vital sector, offering numerous opportunities for growth and innovation.
Market Scope |
|
Report Coverage |
Details |
Page number |
167 |
Base year |
2022 |
Historical year |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.59% |
Market growth 2023-2027 |
USD 24.52 billion |
Market structure |
Fragmented |
YoY growth (%) |
12.4 |
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
Performing market contribution |
North America at 32% |
Key countries |
US, Canada, Germany, UK, China, and India |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
Alchem International Pvt. Ltd., Alkalon AS, Alvogen, Axcentria Pharmaceuticals, British American Tobacco Plc, Cambrex Corp., CHEMNOVATIC Sp. z o.o. Sp. k, Cipla Ltd., Dr. Reddys Laboratories Ltd., Enorama Pharma AB, Imperial Brands Plc, Japan Tobacco Inc., Johnson & Johnson, Lil Drug Store Products Inc., Perrigo Co. Plc, Pfizer Inc., Philip Morris International, Qnovia, Tvape, and Walgreen Co. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.